Jian Q. (Michael) Yu, MD, FRCPC
Chief, Nuclear Medicine and PET
Professor, Department of Diagnostic Radiology
Specialties
Treatment Focus
My main work is in diagnostic imaging using radiotracers for staging, follow-up, and monitoring of various tumors. I also treat patients with unsealed source radiotracer for thyroid cancer, NHL, pancreatic cancer, and bone pain palliation. I’m authorized user for SIR-sphere and Therasphere as well.
Research Program
Treatment Philosophy
Patient first.
Educational Background
- Fellow, American College of Nuclear Medicine, 2009
- Fellow, American College of Nuclear Physicians, 2009
- Fellow, Royal College of Physicians, Canada, 2008
- MD, Beijing Medical University, Beijing, China, 1987
Certifications
- Diplomate, American Board of Nuclear Medicine, certified 2003, recertified 2013
- Nuclear Medicine Specialist, Royal College of Physicians and Surgeons of Canada, 2008
Memberships
- American College of Nuclear Medicine
- American College of Radiology
- Society of Nuclear Medicine and Molecular Imaging
- Radiologic Society of North American
Honors & Awards
- Philadelphia Magazine Top Docs, 2016
- Outstanding Contribution Award, American College of Radiology Imaging Network, 2010
Selected Publications
Yu JQ, Zhuang HM, Xiu Y, Talati E, Alavi A. Demonstration of Increased FDG Activity in Rosai-Dorfman Disease on Positron Emission Tomography. Clinical Nuclear Medicine 29 (3): 209-210 MAR 2004 (PMID: 15162996) PubMed
Yu JQ, Kumar R, Xiu Y, Alavi A, and Zhuang HM. Diffuse FDG uptake in the lungs in patient with aspiration pneumonia on Positron Emission Tomographic imaging. Clinical Nuclear Medicine 29 (9): 567-568 SEPT 2004 (PMID: 15311127) PubMed
Yu JQ, Milestone BD, Parsons R, Doss M, Haas N: Findings of Intra-Mediastinal Gossypiboma with F-18 FDG PET in a Melanoma Patient. Clinical Nuclear Medicine 33(5):344-345, May 2008 (PMID: 18431152) PubMed
Doss M, Zhang JJ, Bélanger MJ, Stubbs JB, Hostetler EB, Alpaugh RK, Kolb H, Yu JQ: Biodistribution and Radiation Dosimetry of the Hypoxia Marker 18F–HX4 in monkeys and humans determined from whole-body PET/CT, Nuclear Medicine Communications 31(12): 1016-24; [Epub 2010 Oct 13] (PMID: 20948452/NIHMSID#: 259162/PMCID: PMC3016990) PubMed
Reddy S, Shaller CC, Doss M, Shchaveleva I, Yu JQ, Robinson MK: Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clinical Cancer Research, 2011 Mar.15; 17(6):1509-1520; [Epub 2010 Dec.21] (PMID: 21177408/PMCID: PMC3060271) PubMed
Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Adams GP, Robinson MK: Impact of Expression System on the Function of the C6.5db PET Radiotracer, Tumor Biology, 2012; 33(3):617-27 [Epub 2012 March 1], PMID:22383295 PubMed
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig CJ, Yu JQ, Vallabhajosula S, Larson SM, Schoder H, English P, Neuberg DS, Martin P, Ely SA, Courtney R, Shaik N, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT and Shapiro GI: Selective CDK4/6 Inhibition with Tumor Responses by PD0332991 in Patients with Mantle Cell Lymphoma, Blood, 2012 119: 4597-4607 with editorial, [Epub 2012 March 1], PMID: 22383795 PubMed
Doss M, Kolb HC, Zhang JJ, Bélanger M, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ*: Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 in monkeys and humans determined from whole-body PET/CT, Journal of Nuclear Medicine 2012; 53:787-795 [Epub 2012 Apr 12], PMID: 22499613 PubMed
Divgi C, Uzzo R, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo J, Larson S, Bevan P, Russo P: PET/CT Identification of Clear Cell Renal Cell Carcinoma: Results of the REDECT Trial. Journal of Clinical Oncology, January 10, 2013: vol. 31, no. 2, 187-194. [Epub Dec. 3, 2012], PMID: 23213092 PubMed
Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R, Galloway T, Ridge J: Extranodal extension of Metastatic Papillary Thyroid Carcinoma: Correlation with biochemical endpoints, nodal persistence and systemic disease progression. Thyroid, 23(9), 1099-1105 [Epub Feb. 19, 2013], PMID: 23421588 PubMed
